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Controlling antimicrobial resistance: Interfering in
the process of natural selection
Johan W Mouton
In this issue of Antimicrobial Resistance and Infection
Control Huttner and colleagues portray a global view from
the World Healthcare-Associated Infections Forum –the
fourth in the series - on a familiar topic: the rapid
spread of antimicrobial resistance [1]. The terminology
‘familiar’ is used here with some emphasis. The increasing
number of papers appearing every year that cry out
against the increasing and rapid emergence of resistance
and a future without antibiotics seem to go hand in
hand with, to speak in statistical terms, a correlation
coefficient that approaches 1. There are, however, a
number of issues that need well deserved attention and
it is in the referred position paper that these are stated
together in a comprehensive review. With an effort not
to repeat everything said already, there are a few of
these issues that need and warrant highlighting, and
these are not so much the problems that are faced, but
more the potential solutions towards it. And then it all
comes back to interfering with the two basic principles
that govern emergence and spread of resistance. The
first is natural selection (a term used to describe the
process in sensu stricto, although admittedly the very
fact that resistance will emerge under selection pres-
sure does have a teleological ring to it) and the second
dissemination – interfering in the latter being a specific
element of the title of the Journal.
Natural selection will, as a basic process in nature, always
give rise to emergence of resistance to antimicrobials
in micro-organisms in the presence of antimicrobials,
be it that the frequency (or probability of occurrence)
is of course dependent on many factors. Although the
continuous cry for new antimicrobials is certainly and
highly justified, and mechanisms to stimulate development
of new antimicrobials may even require more attention
than presently is the case, these new agents will be losing
their potential as soon as they become available for use if
no mechanisms are put in place to restrict its usage in a
sensible manner. As noted by Huttner and colleagues,
the present situation was prophesied by Alexander
Fleming in his acceptance speech of the Nobel prize in
1945. Yet, in the ensuing years, there was a sales and
marketing process of almost any drug that could be
found that had some antimicrobial activity and indications
to use became manifold, often without too much evidence.
Serious problems with other drugs put an end to that
process through the Kefauver and Harris Amendments
in 1962 –at least in the US– although it would take
years before rigorous testing and development became
the standard. But use still appears to be manifold –
how else can it be explained that the per capita use of
antimicrobials is almost 20 fold more in one country
than that in another?
The main challenge therefore is how to influence the
process of natural selection, in other words how to
minimize exposure of micro-organisms to antimicrobials
without compromising their efficacy or restricting its use
to those patients that need them. Or from a different
perspective, optimizing the use of antimicrobials that we
have and thereby preserving antibiotics for the future.
One of the obvious answers is formulated by Huttner
and colleagues: antibiotic conservation or stewardship
programs. These programs are increasingly receiving
attention as more and more evidence is collected
suggesting that these actually work. As an example,
The Netherlands government recently issued a statement
strongly supporting the installation of so-called A-teams
(antibiotic stewardship teams) in every hospital in country
with the Health Inspectorate given the assignment to
oversee that, within two years, these have come true.
The A-teams are typically multidisciplinary and will
consist of a clinical microbiologist, an infectious disease
physician and a hospital pharmacist. Yet even these teams
cannot function without proper guidance of evidence
based criteria. What is the optimal duration of therapy?
What is the optimal dosing regimen and antimicrobial
choice? These are all questions that clearly need to be
answered and will require a huge effort.
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It is obvious that antimicrobial stewardship and hospital
hygiene measures introduce costs that hospital directors
are not happy to be confronted with in the face of
constrained budgets. This is even more the case in
long-term care facilities and nursing homes. Yet in the
long run, prevention of resistance is not only for the
benefit for patients, it is less expensive as well. With
the (probably under-) estimated cost of 55 billion per
year in the US alone, any measure that significantly
reduces resistance will be cost-effective for society as a
whole. This requires mechanisms in society that promote
these measures. Unfortunately, these are still lacking
both in the developed world as well as in third world
countries. There is clearly something wrong in the
checks and balances of the system.
As the authors indicate, it is not only human consump-
tion that requires measures, but also the extensive use
in animal husbandry. Using The Netherlands again as
an example, it is noteworthy that antimicrobial use in
humans in The Netherlands has traditionally been one
of the lowest in Europe, but at the same time one of the
highest in animal husbandry. This paradox was recognized
by the government a few years ago and targets to reduce
antibiotic consumption and thereby exposure were set.
To reach these goals, other stringent measures were
taken over time: farmers now have to report antimicrobial
use in a central database and, on the prescription side,
veterinarians have to report as well. Taken together, a
significant reduction in sales and use has been reached
in just a couple of years.
These examples demonstrate that if certain check and
balance mechanisms are imposed, interfering in the
process of natural selection is possible. However, it is
not an easy process as any change in behaviour is not
easy and certainly not always accepted. This is clearly
demonstrated by the opposition and demonstrations by
French veterinarians this week against an upcoming
law supposedly restricting the right to prescribe certain
antibiotics (which in some other countries has been put
into law for some time already!).
The continuing use, or rather abuse of antibiotics
favours emergence and spread of resistance. Micro-
organisms are not restricted by borders, do not care
whether they are in the hospital or outside. They thrive
wherever they have an opportunity to do so and we, as
humans, have created that environment for resistant
bacteria. This needs to stop. The concluding remarks
in the Huttner et al., [1] paper are more than justified,
but can be summarized as: action now, now, now! It
might not be too late.
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